Clinical Trial Update: Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin (MK-2355-004) [Phase 2]

View source ↗

Summary

Phase 2 trial update shows safety and antiviral activity of IDX184 when combined with pegylated interferon and ribavirin in chronic hepatitis C infection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• IDX184 (IDX184)
• Peginterferon alfa-2a (peginterferon alfa-2a)
• Ribavirin (ribavirin)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Chronic Hepatitis C Infection | Phase 2 | Status: COMPLETED